KIMBERLY GROSSNICKLE: Open Payments
NPI 1134685183 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,295 in 129 payments from 49 companies in 2025. Trend: 2023 $1,270 · 2024 $1,526 · 2025 $3,295
Food & beverage: $3,202Education: $93
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 11 | $351 |
| Merck Sharp & Dohme LLC | 9 | $259 |
| AstraZeneca Pharmaceuticals LP | 10 | $234 |
| Novartis Pharmaceuticals Corporation | 12 | $216 |
| PFIZER INC. | 6 | $169 |
| ABBVIE INC. | 6 | $153 |
| GlaxoSmithKline, LLC. | 5 | $139 |
| TG Therapeutics, Inc. | 1 | $108 |
| Alnylam Pharmaceuticals Inc. | 5 | $101 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $85 |
Products named: KEYTRUDA, ERLEADA, EPKINLY, BRIUMVI, TECVAYLI, ENHERTU, Nubeqa, AMVUTTRA.
Industry payments across MD — which companies pay providers there.
